Neobe Therapeutics Funding Round

11/10/2026

Venture Equity

$6,800,000

Seed

Neobe Therapeutics will use the $6.8 million funding to advance its lead programme, NEO22, through preclinical studies towards an Investigational New Drug (IND) filing planned for 2028. The investment will support the development of its engineered bacterial therapeutics, which are designed to break down the physical barriers surrounding solid tumours and enable cancer drugs and immune cells to reach cancer cells more effectively. The company will also strengthen its leadership team and accelerate its clinical development plans. Additionally, a further tranche of the current seed round is expected to finance its first-in-human clinical trial.

Private & Independent

Biopharmaceutical

Salisbury House, Station Road
Cambridge, England, CB1 2LA
UK

Undisclosed

Neobe Therapeutics is a UK-based biotechnology company developing a synthetic biology platform that uses engineered live bacteria to target solid tumours. Its technology is designed to break down the protective barriers surrounding tumours, allowing immune cells and existing immunotherapies to reach cancer cells more effectively. Its research focuses on colorectal, pancreatic and breast cancers.